Abbott Laboratories shares slid -4.3% this afternoon. Here's what you need to know about the Large-CapPharmaceutical company:
-
Abbott Laboratories has logged a 22.5% 52 week change, compared to 31.5% for the S&P 500
-
ABT has an average analyst rating of buy and is -9.54% away from its mean target price of $125.74 per share
-
Its trailing earnings per share (EPS) is $3.26, which brings its trailing Price to Earnings (P/E) ratio to 34.9. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $5.11 and its forward P/E ratio is 22.3
-
The company has a Price to Book (P/B) ratio of 5.11 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 1.7, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
ABT has reported YOY quarterly earnings growth of 55.0% and gross profit margins of 0.6%
-
Abbott Laboratories's revenues have an average growth rate of 5.0% with operating expenses growing at 2.8%. The company's current operating margins stand at 15.0%